Keywords: Antineoplastic agents/adverse effects; Angiogenesis inhibitors; Cardiotoxins; Vascular endothelial growth factor; Bevacizumab; Sorafenib; Sunitinib; Vandetanib; Aflibercept;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Angiogenesis; Bevacizumab; Aflibercept; Ramucirumab; Second line; Colorectal cancer;
Keywords: aflibercept; bevacizumab; diabetes; diabetic macular edema; diabetic retinopathy; intravitreal anti-VEGF; laser photocoagulation; ranibizumab; retina; vascular endothelial growth factor; VEGF;
Keywords: aflibercept; Avastin™; bevacizumab; diabetic macular edema; diabetic retinopathy; glycated hemoglobin (A1C); insulin therapy; metabolic parameters; ranibizumab; VEGF-inhibitorsaflibercept; AvastinMC; bévacizumab; œdème maculaire diabétique; hémoglobine gl
Keywords: Nanotechnology; Nanoparticles; Retina; Vitreous; Sustained release; AMDCyclosporine A; Difluprednate; Aflibercept; Bevacizumab; Pegaptanib; Ranibizumab
Keywords: aflibercept; age-related macular degeneration; pegaptanib; ranibizumab; vascular endothelial growth factor
Choroidal osteoma with choroidal excavation and associated neovascular membrane: An OCT-angiography study
Keywords: Aflibercept; OCT-angiography; Vascular spiders; Choroidal excavation; Choroidal osteoma; Choroidal neovascularisation; Aflibercept; AngiografÃa-TCO; Arañas vasculares; Excavación coroidea; Osteoma coroideo; Neovascularización coroidea;
Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept
Keywords: Age-related macular degeneration; Anti-VEGF; Aflibercept; Individualized regimen; Dégénérescence maculaire liée à l'âge; Anti-VEGF; Aflibercept; Régime individualisé;
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial
Keywords: Elderly; Aflibercept; mCRC; Second-line; VEGF-Trap; VELOUR;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
Keywords: Aflibercept; Bevacizumab; Cetuximab; Infection; Pertuzumab; Small-molecule inhibitors; Trastuzumab; Tyrosine kinase inhibitors; VEGF-targeted agents;
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
Keywords: age-related macular degeneration; vascular endothelial growth factor; ranibizumab; lucentis; aflibercept; eylea; switch; refractory;
Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria
Keywords: Phagocytosis; Latex beads; Bevacizumab; Ranibizumab; Aflibercept; Anti-VEGF; Cybrids; Retinal pigment epithelium; Mitochondria; Age-related macular degeneration;
Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium
Keywords: Bevacizumab; Ranibizumab; Aflibercept; Rituximab; RPE; Senescence; Aging;
Hemangioma capilar retiniano yuxtapapilar bilateral: utilidad de aflibercept en el manejo de sus complicaciones
Keywords: Feocromocitoma; Hemangioma capilar retiniano; Hemorragia subretiniana yuxtapapilar; Enfermedad de von Hippel Lindau; Aflibercept; Phaeochromocytoma; Retinal capillary haemangioma; Subretinal juxtapapillary haemorrhage; Von Hippel Lindau disease; Afliberce
Enfermedad de Coats con edema macular sensible al aflibercept y láser argón
Keywords: Enfermedad de Coats; Láser argón; Ranibizumab; Aflibercept; Coats' disease; Argon laser; Ranibizumab; Aflibercept;
Devastadora complicación tras tratamiento con aflibercept
Keywords: Perforación intestinal; Aflibercept; Neoplasia colorrectal; Agentes antiangiogénicos; Intestinal perforation; Aflibercept; Colorectal neoplasms; Antiangiogenic agents;
Aflibercept in macular edema secondary to retinal vein occlusion: A real life study
Keywords: Aflibercept; Macular edema; Retinal vein occlusion;
Choroidal neovascularization secondary to tuberculosis: Presentation and management
Keywords: Choroidal neovascularization; Tuberculosis; Tuberculous chorioretinitis; Aflibercept;
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
Keywords: Anti-VEGF; Bevacizumab; Ranibizumab; Aflibercept; Cornea;
Estrategia «Tratar y Extender» con aflibercept: efecto en diferentes tipos de neovascularización coroidea asociada a la edad
Keywords: Aflibercept; Tratar y extender; Proliferación angiomatosa retiniana; Neovascularización coroidea; TomografÃa de coherencia óptica de dominio espectral; Grosor coroideo; Aflibercept; Treat and extend; Retinal angiomatous proliferation; Choroidal neovas
Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells
Keywords: Retinal endothelial cells; Aflibercept; Fc fusion protein; IgG; Neonatal Fc receptor; Internalization; Transport; Transcytosis; DMSO; dimethyl sulfoxide; EEA1; early endosome antigen 1; Fc; fragment crystalisable; FcRn; neonatal Fc receptor; FBS; fetal bo
Réponse visuelle et anatomique en condition de « vraie vie » du traitement par aflibercept chez les patients naïfs atteints de dégénérescence maculaire liée à l'âge exsudative
Keywords: Dégénérescence maculaire liée à l'âge exsudative; Patient naïf; Aflibercept; Ranibizumab; Anti-VEGF; Acuité visuelle; Ãpaisseur maculaire centrale; Exudative age-related macular degeneration; Treatment-naive patient; Aflibercept; Ranibizumab; A
Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE
Keywords: Glycosaminoglycans; Sulodexide; Aflibercept; VEGF; Diabetic retinopathy;
Efficacy of aflibercept (EYLEA®) on inhibition of human VEGF in vitro
Keywords: EYLEA®; HUVEC; Aflibercept; VEGF; VEGF-trap;
Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
Keywords: Ranibizumab; Aflibercept; Age-related macular degeneration;
Müller glia activation by VEGF-antagonizing drugs: An in vitro study on rat primary retinal cultures
Keywords: Müller glia; Primary retinal cultures; Vascular Endothelial Growth Factor; Glial Fibrillary Acidic Protein; Aquaporin 4; K+ channel 4.1; Aflibercept; Ranibizumab; VEGF; Vascular Endothelial Growth Factor; GFAP; Glial Fibrillary Acidic Protein; ERK 1/2; E
Algorithme de prise en charge de la dégénérescence maculaire liée à l'âge avec aflibercept : application en vraie vie
Keywords: Algorithme; Aflibercept; Dégénérescence maculaire néovasculaire liée à l'âge; Traitement; Vraie vie; Algorithm; Aflibercept; Wet age-related macular degeneration; Treatment; Real-life;
Response to anti-VEGF-A treatment of endothelial cells in vitro
Keywords: VEGF; Endothelial cells; Ranibizumab; Aflibercept; Neovascularization;
Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model
Keywords: Aflibercept; Bevacizumab; Topical treatment; Chemical burn; Corneal neovascularization; NDS; normal donkey serum; PFA; paraformaldehyde; PBS; phosphate-buffered saline; VEGF; vascular endothelial growth factor;
The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium
Keywords: Retinal pigment epithelium (RPE); Bevacizumab; Aflibercept; Rituximab; Neonatal Fc-receptor (FcRn);
Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
Keywords: aflibercept; bevacizumab; neovascular age-related macular degeneration; posterior subtenon triamcinolone; ranibizumab
Aflibercept. Una aproximación a la farmacologÃa
Keywords: FarmacologÃa; Farmacocinética; Anti-VEGF; Aflibercept; Pharmacology; Pharmacokinetics; Anti-VEFG; Aflibercept;
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy
Keywords: Aflibercept; Colorectal cancer; Efficacy; Safety; VEGF-A; VEGF-B; PlGF;
Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway
Keywords: Aflibercept; Bevacizumab; Ranibizumab; Diabetic retinopathy; VEGF;
Traitements anti-angiogéniques dans le cancer colorectal métastatique : peut-on envisager un blocage continu de l'angiogenèse ?
Keywords: Cancer colorectal; Bévacizumab; Aflibercept; Régorafénib; Anti-angiogénique; Traitement d'entretien; Colorectal cancer; Bevacizumab; Aflibercept; Regorafenib; Anti-angiogenic; Maintenance therapy;
Rapid response to intravitreal aflibercept in neovascular age-related macular degeneration after development of tachyphylaxis to bevacizumab and ranibizumab
Keywords: aflibercept; age-related macular degeneration; antivascular endothelial growth factor; bevacizumab; choroidal neovascular membrane; ranibizumab; tachyphylaxis
Antiangiogenic Therapy in Patients With HER2-Positive Metastatic Breast Cancer: A Case Series
Keywords: Aflibercept; Bevacizumab; HER2-positive; Metastatic breast cancer;
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
Keywords: Aflibercept; VEGF Trap; Bevacizumab; Metastatic colorectal cancer; Performance status; Subgroup analysis;
Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells
Keywords: retinal endothelial cells; VEGF inhibition; diabetic retinopathy; aflibercept; ranibizumab; antibody internalization; permeability; neovascularization;
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I study
Keywords: 5-Fluorouracil; Aflibercept; Irinotecan; Phase I study; Solid tumours;
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
Keywords: 5-Fluorouracil; Aflibercept; Irinotecan; Phase I study; Solid tumours;
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Keywords: Aflibercept; Angiogenesis; Pancreatic cancer; VEGF Trap;
VEGF but not PlGF disturbs the barrier of retinal endothelial cells
Keywords: retinal endothelial cells; VEGF; PlGF; bFGF; IGF-1; ranibizumab; aflibercept; diabetic macular edema; bFGF; basic fibroblast growth factor; (i)BREC; (immortalized) bovine retinal endothelial cells; DME; diabetic macular edema; DR; diabetic retinopathy; EC
Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities
Keywords: Aflibercept; Bevacizumab; Cediranib; Metastatic colorectal cancer; Vatalanib
Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management
Keywords: Adverse events; Aflibercept; Antiangiogenic therapy; Bevacizumab; Colorectal cancer; Vascular endothelial growth factor;
Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept
Keywords: Antiangiogenesis; Metastatic colorectal cancer (mCRC); Placental growth factor; VEGF-A; VEGF-B; aflibercept
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
Keywords: Aflibercept; Endometrial cancer; VEGF Trap; Toxicity; Fibroblast growth factor;
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
Keywords: Aflibercept; VEGF trap; Ovarian cancer; Malignant ascites; Phase II study;
A preclinical and clinical review of aflibercept for the management of cancer
Keywords: Aflibercept; Angiogenesis; Bevacizumab; Clinical trial; Review; Safety; Vascular endothelial growth factor; VEGF-Trap; VEGFR